Skip to search formSkip to main contentSkip to account menu

MK-0366

Known as: MK 366, MK 0366, MK366 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1986
1983
1983
Norfloxacin is a new orally absorbed quinoline derivative structurally related to nalidixic acid but showing an expanded… 
1983
1983
Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram… 
1983
1983
Norfloxacin (MK0366) displayed appreciable activity against the great majority of Gram-negative and Gram-positive bacteria. The… 
1983
1983
We compared the activity of norfloxacin (MK-0366), a new orally absorbable derivative of naladixic acid, with those of other… 
1983
1983
The in vitro activity of norfloxacin (MK366) against 477 aerobic gram-negative and gram-positive clinical isolates was compared… 
1983
1983
1. Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikura, T., Mitsuhashi, S.: In vitro antibacterial activity of AM-715, a… 
1983
1983
1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarbo xylic acid (Norfloxacin, MK-0366), a new nalidixic acid… 
Highly Cited
1982
Highly Cited
1982
The in vitro activity of a new oral antimicrobial agent, norfloxacin (MK-0366), was compared with those of nalidixic acid…